Latest News
Practice Newsletter

ALOFT Study Shows Excellent ForeseeHome Patient Compliance

June 2022

A study recently published in Ophthalmology Retina looked at more than 2,000 ForeseeHome patients from five clinics over a 10-year period. In addition to showing an improved long-term visual benefit for ForeseeHome patients, the real-world compliance to frequent testing was also excellent.

The Analysis of the Long-term Visual Outcomes of ForeseeHome Remote Telemonitoring (ALOFT) study1 was designed to understand long-term, real-world visual outcomes and compliance for patients being monitored by the Notal Vision Monitoring Center and performing ForeseeHome preferential hyperacuity perimetry (PHP) tests, as prescribed by their physician.

The AREDS2-HOME study established that patients need to test at least two times a week for the ForeseeHome device to be efficacious.2 Medicare requires eight tests per month for patient reimbursement of the monitoring service. The ALOFT study found that ForeseeHome patients tested an average of 5.2 times per week over a period of 10 years. There are several reasons why the compliance rate is so high:

  • Doctors and staff who refer their patients to the Monitoring Center reinforce the importance of regular ForeseeHome testing
  • Patients receive extensive disease and device education from experienced Certified Ophthalmic Assistants and Technicians (COAs and COTs), so that they understand the importance of early wet AMD detection and how to operate the easy-to-use device.
  • Our Engagement Center team monitors testing compliance and if a patient does not meet the recommended threshold for two consecutive testing cycles (30 days each), we reach out to remind them of the importance of testing regularly and offer to enroll them into our Compliance Coaching Program.
  • The Compliance Coaching Program offers additional patient support and interaction to help patients meet and exceed the minimum testing requirements for best clinical efficacy.

The Notal Vision Monitoring Center, along with the home-based ForeseeHome device and doctor’s reinforcement, provide a remote monitoring service model that is proven to help doctors deliver better long-term visual outcomes with treatment for their AMD patients.

Read the ALOFT Study

Click Here

References

  1. Mathai M., Reddy S., Elman M.J., Garfinkel R.A., Ladd B., Wagner A., Sanborn G.E., Jacobs J., Busquets M., Chew E.Y. on behalf of the ALOFT study group. Analysis of the Long-term visual Outcomes of ForeseeHome Remote Telemonitoring - The ALOFT study. Ophthalmology Retina (2022), doi: https://doi.org/10.1016/j.oret.2022.04.016.
  2. AREDS2-HOME Study Research Group, Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A, Heier JS, Kim JE, Garfinkel R. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology. 2014 Feb;121(2):535-44.

Related News

View Latest News
View Latest News